Deepcell, a company specialising in AI-powered, label-free single cell morphology profiling and sorting, will provide its REM-I platform to integrate into InGel Therapeutics’ therapeutic development pipeline. The companies said the REM-I platform enables high-dimensional morphological insights that accelerate discovery and optimisation of cell therapy candidates.
InGel Therapeutics focuses on engineered, intravitreally delivered cell therapies for disorders such as retinitis pigmentosa. Its leading program, IGT001, combines human rod precursor cells with a biomimetic hydrogel delivery system intended to preserve cone photoreceptors and maintain central vision in patients. The company’s pipeline also includes programs addressing dry age-related macular degeneration, glaucoma, and optic nerve regeneration.
According to the firms, integration of Deepcell’s REM-I will allow InGel to better profile cell states, capture rare phenotypes, and validate therapeutic response with higher resolution. The collaboration is intended to drive innovation in vision-restoring therapeutics and enhance the ability to develop treatments that can preserve or restore vision.
